The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...

Emgality’s most common side effect is a reaction at the injection site. This can cause itching, pain, skin discoloration, or swelling. Other possible side effects include high blood pressure and ...